Search results
New antibiotic based on AstraZeneca drugs kills off deadly bacteria, spares the good guys
FierceBiotech· 6 days agoA new antibiotic based on drugs developed by AstraZeneca can kill off dangerous bacteria that cause...
Lung cancer treatment produces progression-free survival results in Phase III trial
Medical Xpress· 20 hours agoOsimertinib, produced by AstraZeneca under the brand name Tagrisso, significantly extends the time patients live without their cancer worsening, offering the first effective ...
With new Enhertu data, an ADC could overtake chemo in breast cancer
BioPharma Dive via Yahoo Finance· 4 days agoStudy participants had already received one hormone therapy and a type of drug called a CDK 4/6...
AstraZeneca’s breast cancer trial shows ‘unprecedented’ results | Honolulu Star-Advertiser
Honolulu Star-Advertiser· 4 days agoAstraZeneca and Daiichi Sankyo’s Enhertu slows the progression of breast cancer by about five months...
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support...
Morningstar· 5 days agoTempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm ...
Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.
The Wall Street Journal· 4 days agoMore patients can fend off the disease for months or years with targeted or immune-boosting drugs,...
Patient’s Dark Fantasy About Aetna Lands Him in Jail
The Daily Beast via Yahoo News· 2 days agoMany Americans loathe their health insurance providers.A majority say they have severe concerns about financial hardship due to medical bills—even with...
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
BioPharma Dive via Yahoo Finance· 3 days agoWe covered in detail results from a few of the most significant, including for AstraZeneca and...
Cancer Drugs: Deals and Licensing for Antibody-Drug Conjugates
The National Law Review· 14 hours agoAntibody-drug conjugates (ADCs) are a promising class of cancer treatments with an accelerating...
AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored...
Morningstar· 2 days agoCAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4 ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- AbelZeta